May 05, 2026 03:24 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Jolt to TMC! Supreme Court rejects plea challenging central staff deployment at Bengal counting centres | Bangladesh MP warns of refugee crisis if BJP wins West Bengal polls | Diplomatic row: Bangladesh summons Indian envoy over Himanta Biswa Sarma remarks | Supreme Court grants Pawan Khera anticipatory bail in case over allegations against Himanta Biswa Sarma's wife | ‘Not necessary to humiliate me with arrest’: Pawan Khera to SC over remarks on Himanta Biswa Sarma’s wife | ‘Let’s not choose for people capable of choosing’: Supreme Court to Centre on teen pregnancy termination | I-PAC co-founder Vinesh Chandel gets bail after Bengal polls conclude | Exit Polls Give Bengal to BJP—But One Survey Begs to Differ | Big defence push: Rajnath Singh to hold high-stakes talks with Italy’s Defence Minister | “Voting without fear”: PM Modi hails record turnout in West Bengal polls
Johnson&Johnson Vaccine

Kolkata's Peerless Hospital commences Johnson & Johnson vaccine's clinical trial

| @indiablooms | May 08, 2021, at 03:50 am

Kolkata/IBNS: Kolkata's Peerless Hospital has been selected as the only trial venue in the East for Johnson & Johnson for their single-dose vaccine which is currently being used under emergency authorization.

In a statement Dr Subhrajyoti Bhowmick, Clinical trial specialist and clinical Pharmacologist and Director, Clinical Research Peerless Hospital, Kolkata said, " We shall be recruiting 100 participants at this site, six such sites have been selected for this trial of this unique single dose vaccine."

"I am confident we shall get enough volunteers for the clinical trial as vaccine supply is short and the supply of Covishield and Covaxine is less than the huge demand. The ratio shall be 3:1 as three volunteers will get a vaccine while one person shall get a placebo. We are now awaiting the ethics committee approval on which we shall embark on the clinical trials," concluded Bhowmick.

Earlier, Sputnik V, developed by Gamaleya Research Institute of Epidemiology and Microbiology in Russia, has been approved for use in India.

Five million doses of Sputnik V are expected to arrive in India by June.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.